Identification of New Peptide Ligands for Epidermal Growth Factor Receptor Using Phage Display and Computationally Modeling their Mode of Binding

Chemical Biology and Drug Design

Volumn 79, Issue 3, 2012, Pages 246-259

  Hamzeh Mivehroud, Maryam ^a,b   Mahmoudpour, Ali ^a,c   Dastmalchi, Siavoush ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Norgen Biotek Corporation   (Canada)

Author keywords

Assisted model building with energy refinement; Docking; Epidermal growth factor receptor; MM PBSA GBSA; Molecular modeling; Peptide library; Phage display

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE DERIVATIVE;

ARTICLE; BINDING AFFINITY; BIOPANNING; CONTROLLED STUDY; DRUG BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MATHEMATICAL ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; COMPUTER SIMULATION; HUMANS; LIGANDS; PEPTIDE LIBRARY; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR; THERMODYNAMICS;

EID: 84856046186     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01282.x     Document Type: Article

References (70)

1. Wieduwilt M.J., Moasser M.M. (2008) The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci;65:1566-1584.
2. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene;366:2-16.
3. Ferguson K.M. (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys;37:353-373.
4. Sebastian S., Settleman J., Reshkin S.J., Azzariti A., Bellizzi A., Paradiso A. (2006) The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta;1766:120-139.
5. Wheeler D.L., Dunn E.F., Harari P.M. (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol;7:493-507.
6. Jimeno A., Hidalgo M. (2005) Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol;53:179-192.
7. Morgillo F., Lee H.Y. (2005) Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist Updat;8:298-310.
8. Hynes N.E., Lane H.A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer;5:341-354.
9. Okamoto I. (2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J;277:309-315.
10. Soh J., Toyooka S., Ichihara S., Suehisa H., Kobayashi N., Ito S., Yamane M., Aoe M., Sano Y., Kiura K., Date H. (2007) EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib. Lung Cancer;56:445-448.
11. Azzazy H.M., Highsmith W.E. (2002) Phage display technology: clinical applications and recent innovations. Clin Biochem;35:425-445.
12. Pande J., Szewczyk M.M., Grover A.K. (2010) Phage display: concept, innovations, applications and future. Biotechnol Adv;28:849-858.
13. Lowman H.B. (1997) Bacteriophage display and discovery of peptide leads for drug development. Annu Rev Biophys Biomol Struct;26:401-424.
14. Christensen D.J., Gottlin E.B., Benson R.E., Hamilton P.T. (2001) Phage display for target-based antibacterial drug discovery. Drug Discov Today;6:721-727.
15. Smith G.P., Petrenko V.A. (1997) Phage display. Chem Rev;97:391-410.
16. Noren K.A., Noren C.J. (2001) Construction of high-complexity combinatorial phage display peptide libraries. Methods;23:169-178.
17. Sidhu S.S. (2000) Phage display in pharmaceutical biotechnology. Curr Opin Biotechnol;11:610-616.
18. Morishita M., Peppas N.A. (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov Today;11:905-910.
19. Ladner R.C., Sato A.K., Gorzelany J., de Souza M. (2004) Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today;9:525-529.
20. Jenssen H., Aspmo S.I. (2008) Serum stability of peptides. In: Otvos L., editor. Serum Stability of Peptides. Totowa: Humana Press; p. 177-178.
21. Fricker G., Drewe J. (1996) Current concepts in intestinal peptide absorption. J Pept Sci;2:195-211.
22. Lien S., Lowman H.B. (2003) Therapeutic peptides. Trends Biotechnol;21:556-562.
23. Chakraborty C., Jhingan R. (2005) Protein Based Drugs: A Techno-Commercial Approach. Delhi: Biotech Books.
24. Cudic P., Stawikowski M. (2008) Peptidomimetics: Fmoc solid-phase pseudopeptide synthesis. In: Otvos L., editor. Peptide-Based Drug Design. Totowa: Humana Press; p. 223-224.
25. Kay B.K., Kurakin A.V., Hyde-DeRuyscher R. (1998) From peptides to drugs via phage display. Drug Discov Today;3:370-378.
26. Sewald N., Jakubke H.-D. (2002) Peptides: Chemistry and Biology. Weinheim: Wiley-VCH Verlag GmbH.
27. Bradford M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem;72:248-254.
28. Pearlman D.A., Case D.A., Caldwell J.W., Ross W.S., Cheatham T.E., DeBolt S., Ferguson D., Seibel G., Kollman P. (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun;91:1-41.
29. Case D.A., Cheatham T.E. 3rd, Darden T., Gohlke H., Luo R., Merz K.M., Onufriev A., Simmerling C., Wang B., Woods R.J. (2005) The Amber biomolecular simulation programs. J Comput Chem;26:1668-1688.
30. Jones G., Willett P., Glen R.C. (1995) Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol;245:43-53.
31. Jones G., Willett P., Glen R.C., Leach A.R., Taylor R. (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol;267:727-748.
32. Ogiso H., Ishitani R., Nureki O., Fukai S., Yamanaka M., Kim J.H., Saito K., Sakamoto A., Inoue M., Shirouzu M., Yokoyama S. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell;110:775-787.
33. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. (2000) The protein data bank. Nucleic Acids Res;28:235-242.
34. Kollman P.A., Massova I., Reyes C., Kuhn B., Huo S., Chong L., Lee M., Lee T., Duan Y., Wang W., Donini O., Cieplak P., Srinivasan J., Case D.A., Cheatham T.E. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res;33:889-897.
35. Li T., Froeyen M., Herdewijn P. (2008) Computational alanine scanning and free energy decomposition for E. coli type I signal peptidase with lipopeptide inhibitor complex. J Mol Graph Model;26:813-823.
36. Huo S., Massova I., Kollman P.A. (2002) Computational alanine scanning of the 1:1 human growth hormone-receptor complex. J Comput Chem;23:15-27.
37. Ferrari A.M., Degliesposti G., Sgobba M., Rastelli G. (2007) Validation of an automated procedure for the prediction of relative free energies of binding on a set of aldose reductase inhibitors. Bioorg Med Chem;15:7865-7877.
38. Wong S., Amaro R.E., McCammon J.A. (2009) MM-PBSA captures key role of intercalating water molecules at a protein-protein interface. J Chem Theory Comput;5:422-429.
39. Fujiwara S., Amisaki T. (2008) Identification of high affinity fatty acid binding sites on human serum albumin by MM-PBSA method. Biophys J;94:95-103.
40. Massova I., Kollman P.A. (1999) Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J Am Chem Soc;121:8133-8143.
41. Meliciani I., Klenin K., Strunk T., Schmitz K., Wenzel W. (2009) Probing hot spots on protein-protein interfaces with all-atom free-energy simulation. J Chem Phys;131:034114.
42. Guex N., Peitsch M.C. (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis;18:2714-2723.
43. Cohen S. (1997) EGF and its receptor: historical perspective. Introduction. J Mammary Gland Biol Neoplasia;2:93-96.
44. Hammarsten P., Halin S., Wikstöm P., Henriksson R., Rudolfsson S.H., Bergh A. (2006) Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition. Clin Cancer Res;12:7431-7436.
45. Boldrup L., Coates P.J., Hedberg Y., Sjöström B., Dahlqvist A., Nylander K. (2005) Expression of p63, COX-2, EGFR and beta-catenin in smokers and patients with squamous cell carcinoma of the head and neck reveal variations in non-neoplastic tissue and no obvious changes in smokers. Int J Oncol;27:1661-1667.
46. Liang K., Ang K.K., Milas L., Hunter N., Fan Z. (2003) The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys;57:246-254.
47. Dutta P.R., Maity A. (2007) Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett;254:165-177.
48. Wujcik D. (2006) EGFR as a target: rationale for therapy. Semin Oncol Nurs;22:5-9.
49. Jimeno A., Rubio-Viqueira B., Amador M.L., Oppenheimer D., Bouraoud N., Kulesza P., Sebastiani V., Maitra A., Hidalgo M. (2005) Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res;65:3003-3010.
50. Ye F., Gao Q., Cai M.J. (2010) Therapeutic targeting of EGFR in malignant gliomas. Expert Opin Ther Targets;14:303-316.
51. Lo H.W. (2010) Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med;10:44-51.
52. Marshall J. (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer;107:1207-1218.
53. Dassonville O., Bozec A., Fischel J.L., Milano G. (2007) EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol;62:53-61.
54. Tortora G., Bianco R., Daniele G., Ciardiello F., McCubrey J.A., Ricciardi M.R., Ciuffreda L., Cognetti F., Tafuri A., Milella M. (2007) Overcoming resistance to molecularly targeted anticancer therapies: rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat;10:81-100.
55. Jorissen R.N., Walker F., Pouliot N., Garrett T.P., Ward C.W., Burgess A.W. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res;284:31-53.
56. Lax I., Burgess W.H., Bellot F., Ullrich A., Schlessinger J., Givol D. (1988) Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol;8:1831-1834.
57. Tadaki D.K., Niyogi S.K. (1993) The functional importance of hydrophobicity of the tyrosine at position 13 of human epidermal growth factor in receptor binding. J Biol Chem;268:10114-10119.
58. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. 2nd (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther;122:1-8.
59. Wallace A.C., Laskowski R.A., Thornton J.M. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng;8:127-134.
60. Bartels C., Widmer A., Ehrhardt C. (2005) Absolute free energies of binding of peptide analogs to the HIV-1 protease from molecular dynamics simulations. J Comput Chem;26:1294-1305.
61. Woo H.-J. (2008) Calculation of absolute protein-ligand binding constants with the molecular dynamics free energy perturbation method. In: Kukol A., editor. Calculation of Absolute Protein-Ligand Binding Constants with the Molecular Dynamics Free Energy Perturbation Method. Totowa: Humana Press; p. 109-110.
62. Engler D.A., Campion S.R., Hauser M.R., Cook J.S., Niyogi S.K. (1992) Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation. J Biol Chem;267:2274-2281.
63. Koide H., Muto Y., Kasai H., Kohri K., Hoshi K., Takahashi S., Tsukumo K., Sasaki T., Oka T., Miyake Y., Fuwa T., Kohda D., Inagaki F., Miyazawa T., Yokoyama Sh. (1992) A site-directed mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim Biophys Acta;1120:257-261.
64. Nandagopal K., Tadaki D.K., Lamerdin J.A., Serpersu E.H., Niyogi S.K. (1996) The functional importance of Leu15 of human epidermal growth factor in receptor binding and activation. Protein Eng;9:781-788.
65. Campion S.R., Geck M.K., Niyogi S.K. (1993) Cumulative effect of double-site mutations of human epidermal growth factor on receptor binding. J Biol Chem;268:1742-1748.
66. Campion S.R., Biamonti C., Montelione G.T., Niyogi S.K. (1993) The role of asparagine-32 in forming the receptor-binding epitope of human epidermal growth factor. Protein Eng;6:651-659.
67. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., Xu Y., Gu J. (2005) Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J;19:1978-1985.
68. Cavanagh J., Fairbrother W.J., Palmer A.G., Rance M., Skelton N.J. (2007) Protein NMR Spectroscopy: Principles and Practice, 2nd edn. New York: Elsevier Academic Press.
69. Evans J.N.S. (1995) Biomolecular NMR Spectroscopy. New York: Oxford University Press.
70. Gemmecker G. (1999) NMR as a tool in drug research. In: Holzgrabe U., Wawer I., Diehl B., editors. NMR as a Tool in Drug Research. Weinheim: Wiley-VCH Verlag GmbH; p. 140-142.